AbbVie must pay $15 million in Depakote birth-defect trial: jury

A federal jury on Friday awarded $15 million to a 10-year-old boy whose mother blamed his birth defect on AbbVie Inc's (ABBV.N) bipolar disorder drug Depakote that she took while pregnant, in the latest trial among hundreds of lawsuits over the product.

Jurors in federal court in East St. Louis, Illinois, awarded the compensatory damages...

AbbVie must pay $15 million in Depakote birth-defect trial: jury Continue reading…

Crummy situation: Massive food recalls for labeling error

Millions of pounds of food — packaged under major brands including Libby’s, Tyson and Chef Boyardee and ranging from canned spaghetti and meatballs to frozen, ready-to-eat chicken strips — are under recall in the U.S. and Canada because of a labeling error by an unidentified bread crumb supplier.

The recalls started Thursday with an 87-ton...

Crummy situation: Massive food recalls for labeling error Continue reading…

Opioids Over-Prescribed After C-Sections: Studies

THURSDAY, June 8, 2017 (HealthDay News) -- Women are routinely prescribed more opioid painkillers than they need after Cesarean sections, creating a high risk for misuse, a trio of new studies suggests.

C-sections are the most common inpatient surgery in the United States, with 1.3 million procedures performed a year, according to the researchers. But...

Opioids Over-Prescribed After C-Sections: Studies Continue reading…

Harley-Davidson recalls 57,000 motorcycles for oil-line defect

Harley-Davidson is recalling about 57,000 motorcycles worldwide because an oil line can come loose, spewing oil into the path of the rear tire.

The recall covers certain 2017 Electra Glide Ultra Classic, Police Electra Glide, Police Road King, Road King, Road King Special, Street Glide, Street Glide Special, Road Glide and Road Glide Special motorcycles...

Harley-Davidson recalls 57,000 motorcycles for oil-line defect Continue reading…

Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS

The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.

The amount is nearly three times a proposed settlement that the company announced in October.

Read More